The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, David R, Juday, Timothy R, Manthena, Shivaji R, Jing, Yonghua, Sood, Vipan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687623/
https://www.ncbi.nlm.nih.gov/pubmed/26719716
http://dx.doi.org/10.2147/CEOR.S87261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687623/
https://www.ncbi.nlm.nih.gov/pubmed/26719716
http://dx.doi.org/10.2147/CEOR.S87261

Ejemplares similares